Klivira
Request demo

Optimizing Soliqua Prior Authorization for Gastroenterology Practices

Navigating Soliqua prior authorization for gastroenterology practices presents unique administrative complexities, even when managing a drug primarily indicated for diabetes within a GI setting. Klivira streamlines these high-volume PA processes.

Revenue cycle directors and prior authorization coordinators in gastroenterology often face a diverse PA burden, ranging from specialty biologics to advanced imaging. While Soliqua is a high-volume PA target typically managed by endocrinology or primary care, its authorization requirements can still impact a GI practice when patients present with comorbid conditions. Klivira provides a robust solution to automate prior authorization across all drug classes and procedures, ensuring efficiency even for medications outside the primary specialty focus.

Understanding Soliqua's Prior Authorization Landscape

Soliqua, a combination of insulin glargine and lixisenatide, is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans due to its cost and specific prescribing criteria. While primarily indicated for type 2 diabetes, a GI practice may encounter Soliqua PA requests for patients with complex comorbidities or when managing a broader scope of patient needs. Efficiently managing these authorizations is critical to avoid treatment delays.

Prior Authorization Demands in Gastroenterology

Gastroenterology practices face a significant prior authorization burden, driven by the increasing use of specialty biologics, advanced diagnostic procedures, and specific drug therapies. Categories such as IBD biologics, advanced imaging, and certain endoscopic procedures frequently trigger PA requirements, demanding precise documentation and adherence to payer-specific medical necessity criteria. This high volume of diverse PA requests strains administrative resources.

Common PA Triggers in GI Practice

  • IBD biologics, including TNF inhibitors, integrin inhibitors, and IL-12/23 inhibitors, often requiring chronic re-authorization.
  • Hepatitis C direct-acting antivirals, with distinct pathways for treatment-naive versus experienced patients.
  • Advanced imaging studies such as MRCP, MR enterography, and CT enterography for IBD assessment.
  • Endoscopic procedures with specific PA requirements, including capsule endoscopy (CPT 91110) and ERCP for certain indications.
  • Specialty drugs for functional GI disorders, such as eluxadoline (Viberzi) for IBS-D and prucalopride (Motegri) for chronic constipation.
  • Non-routine colonoscopy screenings, including high-risk surveillance and post-polypectomy follow-up.

Documentation Requirements and Denial Prevention

For gastroenterology, adherence to guidelines from bodies like ACG, AGA, and AASLD is paramount for PA approval. Documentation typically includes disease severity scores for IBD (e.g., Mayo score for UC, CDAI or Harvey-Bradshaw for Crohn's), prior conventional therapy trials, and specific diagnostic confirmations. For drugs like Soliqua, general documentation for diabetes management, such as A1c levels and prior medication history, would be critical, alongside any relevant comorbidity documentation, to justify medical necessity.

Minimizing Prior Authorization Denials for GI Therapies

  • Failure to meet step therapy requirements for IBD biologics, including prior conventional therapy or biosimilar trials.
  • Insufficient documentation of disease severity or diagnostic confirmation for conditions like IBD.
  • Gaps in required pre-treatment screenings, such as TB and hepatitis panels before biologic initiation.
  • Inappropriate-use criteria for advanced imaging or endoscopic procedures, lacking clinical correlation.
  • Misclassification of treatment-naive versus treatment-experienced status for Hep C DAAs or IBD biologics.

Klivira's Solution for Comprehensive Prior Authorization

Klivira's platform provides a unified approach to prior authorization, capable of managing the diverse requirements of gastroenterology and other specialties. By integrating with existing EMR systems via SMART on FHIR, Klivira automates the extraction of clinical data, populating X12 278 and ePA forms. This reduces manual effort and accelerates submission for all types of PAs, including high-volume drugs like Soliqua and complex GI procedures, ensuring compliance with Da Vinci PAS and other industry standards.

Frequently asked questions

How does Klivira handle Soliqua PA when it's prescribed by a GI specialist?

Klivira's platform is designed to process prior authorizations for any drug or procedure encountered within a practice. For Soliqua, the system leverages its extensive policy library to identify payer-specific requirements, such as A1c levels and prior medication trials. By integrating with your EMR, Klivira automates data collection and submission, ensuring all necessary clinical information is included, regardless of the prescribing specialty.

What specific gastroenterology guidelines does Klivira incorporate for PA automation?

Klivira's intelligent logic incorporates guidelines from major bodies such as ACG, AGA, and AASLD for conditions relevant to gastroenterology. This includes step-therapy sequencing for IBD biologics, documentation requirements for hepatitis C DAAs, and medical necessity criteria for advanced imaging and endoscopic procedures, ensuring submissions align with established clinical pathways.

Can Klivira manage both medical and pharmacy benefit PAs for GI biologics?

Yes, Klivira is equipped to manage prior authorizations across both medical and pharmacy benefits. For GI biologics, which can often switch between provider-administered infusions (medical benefit) and self-administered injections (pharmacy benefit), Klivira ensures appropriate routing and documentation, streamlining the process regardless of the administration mode or benefit type.

How does Klivira address the chronic re-authorization burden for IBD biologics?

Klivira's platform includes automated workflows for periodic re-authorization, a critical feature for chronic treatments like IBD biologics. The system tracks re-authorization deadlines, proactively prompts for updated documentation of disease response, and facilitates timely resubmission to payers, significantly reducing the administrative overhead associated with ongoing PA management.

Does Klivira help with documentation for advanced GI imaging PAs?

Yes, for advanced GI imaging such as MRCP or MR enterography, Klivira assists by ensuring all required clinical questions, prior imaging history, and conservative-evaluation workup documentation are captured and submitted. This helps meet payer-specific medical necessity criteria and reduces denials related to insufficient clinical justification.

Related coverage

Other soliqua prior authorization by payer

Other soliqua prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo